These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prenatal diagnosis and genetic counseling of cystic fibrosis.
    Author: Niermeijer MF, Halley DJ, Kleijer WJ, Neijens HJ, Sinaasappel M.
    Journal: Acta Paediatr Scand Suppl; 1989; 363():20-4. PubMed ID: 2701920.
    Abstract:
    The number of DNA markers at the chromosome 7-locus of the putative CF gene has markedly increased in recent years, also as a result of intensive research into the possible "candidate" gene. In studies of families with one or more affected children, 97.5% of families are now fully informative, allowing a prenatal diagnosis by chorionic villus sampling in the 10th week and DNA-analysis, which will usually give now a diagnosis with a remaining risk of less than 1%. The microvillar enzyme test in amniotic fluid after amniocentesis in the 18th week will remain an alternative for couples who have a high prior risk, but are either not informative at DNA analysis, or where no information on a (deceased) index case (previous affected child) is available. The risk for a wrong classification is in the order of a few percent (in a 1:4 prior risk case) and careful discussion of the limitations are needed when this test is applied to cases with a lower prior risk. The linkage disequilibrium established for a number of RFLP's (Restriction Fragment Length Polymorphisms), as detected by various probes and various restriction enzymes around the CF locus has opened the possibility to refine the risk estimation of heterozygosity for individuals outside families with CF-affected children. The presence of certain haplotypes may change the risk for being CF heterozygote from +/- 1:7 to 1:250, as compared to a population risk of +/- 1:25.(ABSTRACT TRUNCATED AT 250 WORDS)
    [Abstract] [Full Text] [Related] [New Search]